In a landmark pharmaceutical patent dispute, the Delaware District Court entered final judgment on August 14, 2024 in Case No. 1:21-cv-01338, delivering a critical win to AstraZeneca despite a jury finding of induced infringement. The court determined that AstraZeneca induced infringement of claims 1, 3, and 9 of U.S. Patent No. 10,603,314 and claim 1 of U.S. Patent No. 10,596,162—both covering methods of treatment using the blockbuster cancer drug Tagrisso® (osimertinib)—but invalidated all asserted claims under 35 U.S.C. § 112 for both lack of enablement and lack of written description, rendering the infringement finding moot.

This case carries profound implications for pharmaceutical and biotech patent practitioners. The dual invalidity finding on § 112 grounds—even after a jury concluded infringement occurred—underscores the critical importance of robust patent drafting in complex oncology drug patent portfolios. IP teams at biopharmaceutical companies and in-house counsel monitoring Tagrisso® litigation must reassess how broadly worded treatment method claims are supported in the specification, particularly where pioneering drug therapies are involved.

Case Overview

The Parties

The Patents at Issue

U.S. Patent Nos. 10,603,314 and 10,596,162 cover methods of treating cancer patients—specifically those with HER2 or EGFR mutations—using irreversible tyrosine kinase inhibitors. The asserted claims describe treatment protocols targeting specific patient populations, including those who have progressed on prior therapies, and are directed at the clinical use of compounds like neratinib and related agents. These patents are relevant to the broader class of EGFR-targeted oncology therapeutics, including osimertinib (Tagrisso®), where treatment-method claims govern how oncologists administer approved therapies.

• • US10596162B2
• • US10603314B2

Legal Representation

Plaintiff Counsel: Morris, Nichols, Arsht & Tunnell LLP (lead: Alexis Adian Smith)
Defendant Counsel: Shaw Keller LLP (lead: Alexander Trzeciak)

Litigation Timeline & Procedural History

Filed on September 22, 2021 in the District of Delaware—the preeminent venue for pharmaceutical patent litigation given its concentrated expertise in Hatch-Waxman and biologic patent disputes—this case proceeded as a first-instance district court action before Chief Judge Matthew F. Kennelly. Delaware’s selection by plaintiffs reflects both strategic considerations around judicial familiarity with pharmaceutical IP and AstraZeneca’s registered presence in the jurisdiction. The case was categorized as a direct infringement action under the patent act, not a Hatch-Waxman paragraph IV dispute, targeting AstraZeneca’s commercial Tagrisso® products.

The litigation ran for 1,057 days—nearly three years—before reaching final resolution on August 14, 2024, reflecting the complexity of a case that proceeded through both a full jury trial (verdict rendered May 17, 2024) and a subsequent bench trial on equitable and invalidity defenses, with findings issued August 6, 2024. Post-trial motions were resolved on August 14, 2024, when the court entered final judgment, vacating its earlier non-final judgment of May 28, 2024. This dual-track trial structure—jury deciding infringement, bench trial addressing invalidity under § 112—is procedurally significant and signals the court’s management of complex pharmaceutical patent disputes involving mixed legal and equitable issues.

The Verdict & Legal Analysis

Outcome

The Delaware District Court entered final judgment in favor of AstraZeneca on August 14, 2024. While the jury found that AstraZeneca induced infringement of claims 1, 3, and 9 of the ‘314 patent and claim 1 of the ‘162 patent, the court invalidated all asserted claims under 35 U.S.C. § 112 for both lack of enablement and lack of written description following a bench trial. No damages were awarded and no injunction was entered, as the invalidity finding extinguished any actionable infringement claim. Judgment was entered in favor of Wyeth on certain of AstraZeneca’s counterclaims (Counts 1, 3, and 5), while AstraZeneca prevailed on its invalidity counterclaims (Counts 2 and 4).

Verdict Cause Analysis

The court’s invalidity determination under 35 U.S.C. § 112 rested on two independently sufficient grounds that together rendered the asserted claims unenforceable:

• Lack of enablement under § 112(a): The court found that the asserted claims of the ‘314 and ‘162 patents were not enabled because the specification did not teach a person of ordinary skill in the art how to practice the full scope of the claimed methods without undue experimentation, particularly given the breadth of the patient populations and treatment conditions encompassed by the claims.
• Lack of written description under § 112(a): The court separately concluded that the patent specifications failed to demonstrate that the inventors were in possession of the full scope of the claimed inventions at the time of filing, a particularly demanding standard when broad method-of-treatment claims cover diverse oncology indications and patient subgroups.
• Induced infringement was nevertheless established: Despite the invalidity ruling, the jury’s finding that AstraZeneca induced infringement through Tagrisso® prescribing information and physician-directed labeling was not disturbed, demonstrating that the underlying conduct met the legal standard for inducement—a significant factual finding even if rendered non-actionable by invalidity.
• Post-trial motions resolved concurrently with bench trial findings: The court’s August 14, 2024 final judgment resolved all pending post-trial motions alongside the bench trial conclusions, vacating the non-final May 28, 2024 judgment and establishing a clean, final, and immediately appealable order.

Legal Significance

1. 1. This decision reinforces the heightened § 112 enablement and written description standards applied to broad pharmaceutical method-of-treatment claims post-Amgen v. Sanofi, signaling that courts will scrutinize whether oncology patent specifications adequately support claims covering wide patient populations and treatment scenarios.
2. 2. The procedural split—jury trial on infringement, bench trial on § 112 invalidity—reflects an important strategic dynamic in pharmaceutical patent litigation where defendants may prefer judge-decided invalidity issues, and this outcome may influence how parties in similar cases request bifurcation or structure their trial approaches.
3. 3. As a final and appealable judgment explicitly noted in the order, this case is positioned for Federal Circuit review, and any appellate ruling on the § 112 written description or enablement standards as applied to EGFR inhibitor treatment methods could have significant precedential impact across the oncology patent landscape.

Strategic Takeaways

For Patent Attorneys:

• When drafting method-of-treatment claims for oncology therapeutics, ensure the specification provides working examples and clinical data sufficient to enable the full scope of claimed patient populations and treatment regimens—broad functional claiming without commensurate disclosure is increasingly vulnerable post-Amgen.
• Consider requesting bifurcated trials in pharmaceutical patent cases where § 112 invalidity defenses are strong, allowing bench trial resolution of invalidity to potentially moot damages exposure from a jury infringement finding, as AstraZeneca effectively achieved here.
• The jury’s induced infringement finding—based on Tagrisso® labeling and prescribing information—confirms that detailed product labeling directing physicians to administer a drug in a patented manner continues to satisfy the specific intent requirement for induced infringement, a critical drafting and litigation consideration.
• Assess the appellate posture carefully: with a final and appealable judgment entered, plaintiffs holding invalidated patents covering commercially important drugs have strong incentives to seek Federal Circuit review, and practitioners should monitor any appeal for § 112 standard clarification affecting pending pharmaceutical patent prosecution.

For IP Professionals:

• Conduct an immediate portfolio audit of method-of-treatment patents in your oncology or biologics pipeline to evaluate whether claim scope is adequately supported by clinical and mechanistic data in the specification, particularly for claims covering multiple patient subgroups or progressive treatment lines.
• Implement a litigation monitoring protocol for this case’s Federal Circuit appeal, as any modification of the § 112 enablement or written description standards applied to EGFR-targeted therapies could directly affect the enforceability of analogous claims in your portfolio or those of competitors.

For R&D Teams:

• R&D teams developing EGFR or HER2-targeted therapies should conduct freedom-to-operate analysis not only on product composition claims but also on method-of-treatment claims in the same technology space—even invalidated claims may be revived on appeal, and competitor patents with similar claim structures remain active risks.
• When generating clinical and preclinical data for new oncology drug candidates, work with patent counsel to ensure that data comprehensively covers the full intended claim scope from the earliest filing date, as post-filing data generally cannot cure § 112 written description deficiencies identified at the time of prosecution.